Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Fineline Cube Aug 19, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Fineline Cube Aug 19, 2026
Company Deals

Merck KGaA Expands High-Purity Reagents Production in Nantong, China with EUR 70 Million Investment

Fineline Cube Jun 30, 2023

Germany-based Merck KGaA (NYSE: MRK) has announced plans to expand production capacity for highly-purified reagents...

Company Deals

Shanghai Pharmaceuticals’ MediTrust Health Partners with Yuanda Shuyang on Rare Disease Treatment Model

Fineline Cube Jun 29, 2023

Shanghai Pharmaceuticals Holding Co., Ltd’s (SHA: 601607, HKG: 2607) subsidiary, MediTrust Health, which specializes in...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Receives NMPA Approval for ALK+ NSCLC Treatment

Fineline Cube Jun 29, 2023

China-based Qilu Pharmaceutical has announced that its Category 1 chemical drug, iruplinalkib, an ALK inhibitor,...

Company Drug

Jiangsu Hengrui’s Oteseconazole (SHR8008) Approved by NMPA for Severe Vulvovaginal Candidiasis

Fineline Cube Jun 29, 2023

The National Medical Products Administration (NMPA) has granted approval to China-based Jiangsu Hengrui Pharmaceuticals Co.,...

Company Deals

WestGene Biopharma Secures $42 Million in Funding to Advance mRNA Therapeutics

Fineline Cube Jun 29, 2023

Chengdu-based mRNA specialist WestGene Biopharma has reportedly raised USD 42 million via a funding round,...

Company Deals

Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China

Fineline Cube Jun 29, 2023

US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical...

Company Drug

EOC Pharma’s Lusutrombopag Receives NMPA Approval for Chronic Liver Disease Treatment

Fineline Cube Jun 29, 2023

China-based EOC Pharma Group has announced that its drug, lusutrombopag, has received marketing approval from...

Company Deals

Changchun BCHT Biotechnology to Acquire Full Stake in mRNA R&D Firm Transcend Biomedical

Fineline Cube Jun 29, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced its intention to invest in...

Company Drug

Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablets for AIS Accepted by NMPA for Review

Fineline Cube Jun 29, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that the National Medical Products Administration...

Company Drug

Shanghai Junshi Biosciences Gets FDA Approval for Phase III Study of Tifcemalimab in Small-Cell Lung Cancer

Fineline Cube Jun 29, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877) has announced receiving approval from the US Food...

Company Deals

Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion

Fineline Cube Jun 29, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD...

Company Drug

AIM Vaccine Receives NMPA Approval for mRNA Vaccine Clinical Study Targeting COVID-19 Variants

Fineline Cube Jun 29, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...

Company Deals

Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share

Fineline Cube Jun 29, 2023

Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Shandong Buchang Pharmaceuticals’ BC001 Gets Clinical Trial Approval for Solid Tumors

Fineline Cube Jun 29, 2023

Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced receiving clinical...

Company Drug

Beijing Tiantan Biological Completes Phase I Study for Recombinant Coagulation Factor VIIa

Fineline Cube Jun 28, 2023

China-based Beijing Tiantan Biological Products Co., Ltd (SHA: 600161) has announced the conclusion of a...

Policy / Regulatory

Shanghai’s SMPA Notification: Non-Winning Bids in VBP Round 8 Can Avoid “Higher Price” Label

Fineline Cube Jun 28, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification concerning the 8th round of...

Company Legal / IP Policy / Regulatory

US FDA Issues Warning Letter to Chengdu KeCheng Fine Chemicals Over Communication Failures

Fineline Cube Jun 28, 2023

The US FDA’s Center for Drug Evaluation (CDE) issued a warning letter to China-based Chengdu...

Company Drug

Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging

Fineline Cube Jun 28, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...

Company Drug

Teva Pharmaceutical’s Copaxone Approved by NMPA for Multiple Sclerosis Treatment in China

Fineline Cube Jun 28, 2023

The National Medical Products Administration (NMPA) website has indicated that Israel-based Teva Pharmaceutical Industries’ (NYSE:...

Company

Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health

Fineline Cube Jun 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of...

Posts pagination

1 … 553 554 555 … 710

Recent updates

  • Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China
  • Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists
  • FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19
  • Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting
  • Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Company Medical Device

Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.